yes, it's expensive when you look at it on a multiple basis but on a growth basis and peter lynch saysficant indicator of price performance over time. this has earnings growth at the forefront of a.i. they're really tough to bet against them. >> all right, let's turn then to a very different way to play a.i., gina. you came up with as midtronnic. explain. >> medtronic is one of the devicemakers. like i said it is eating everything and health care is no exception. medtronic has gotten regulatory confirmation for five a.i. efforts that -- a.i. products that they are doing including an a.i. generative system for diabetes, which is mini med and they have an a.i. product for endoscopy, so lots of ways to do it. in fact, just last quarter you heard about medtronic talking about the adoption of its a.i. surgical planning for spinal surgery that has been shown to improve outcomes for spinal surgery, so this is one of the plays where you see an industry where, you know, demand is nearly unlimited. resources are very limited. a.i. could actually have an enormous impact on driving demand and, qui